Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Eli Lilly and Company, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Zepbound, all published on August 5, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Zepbound
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Eli Lilly and Company, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Zepbound, all published on August 5, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Zepbound. Shared-story counts are live from our verified record — not editorial picks.
Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.